RJA
AEMD icon

Raymond James & Associates’s Aethlon Medical AEMD Stock Holding History

Raymond James & Associates’s Portfolio AEMD Stock Details AEMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed -$13K – 3584
2018
Q1 		$13K Hold
1
– – ﹤0.01% 3403
2017
Q4 		$19K Hold
1
– – ﹤0.01% 3342
2017
Q3 		$18K Buy
+1
New +$21.5K ﹤0.01% 3319

Other funds holding AEMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFN
Cordasco Financial Network Naples, Florida $138M AUM 10.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SAM
Shamrock Asset Management Dallas, Texas $128M AUM 2.65% 1-Year Est. Return

Raymond James & Associates's AEMD Position: Q2 2018 in Review

Raymond James & Associates sold out of Aethlon Medical (AEMD) in Q2 2018, closing a stake of 1 share — an estimated $13K sold.

Raymond James & Associates first reported a position in AEMD in Q3 2017 and held it in 3 quarters. The position peaked at $19K in Q4 2017. 12 funds tracked by Wall St. Rank hold AEMD as of Q2 2018.

  • Raymond James & Associates reported no remaining Aethlon Medical position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 1 Aethlon Medical share in Q2 2018, an estimated $13K.
  • Raymond James & Associates first reported a position in Aethlon Medical in Q3 2017 and held it in 3 quarters.
  • Raymond James & Associates's Aethlon Medical position peaked at $19K in Q4 2017.
  • 12 funds tracked by Wall St. Rank held Aethlon Medical as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.